A successful treatment of relapsed primary CNS lymphoma patient with intraventricular rituximab followed by high-dose chemotherapy with autologous stem cell rescue

Sung Jin Hong, Jin Seok Kim, Jong Hee Chang, Kyoung Min Kim, Soo Jeong Kim, Hye Won Lee, Jone Won Cheong, Seung Tae Lee, Yoo Hong Min

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The prognosis for patients with primary central nervous system (CNS) lymphoma (PCNSL) who relapse after the initial response is usually poor. A standard treatment for relapsed PCNSL has not yet been identified because of the heterogeneity of the therapies employed and the lack of large, prospective clinical trials. We describe a 46-year-old relapsed PCNSL patient who was successfully treated with intraventricular applications of rituximab to minimize neurotoxicity, 2 cycles of salvage chemotherapy with etoposide, ifosfamide, and cytarabine (VIA) regimen and high-dose chemotherapy with autologous stem cell rescue. The high-dose chemotherapy consisted of bischloroethylnitrosourea, etoposide, cytarabine, and melphalan (BEAM) regimen. Partial remission was detected after intraventricular rituximab therapy and the patient has been in complete remission without evidence of neurotoxicity for 28 months after high-dose chemotherapy with autologous stem cell rescue. This case indicates a new appropriate treatment guideline in relapsed PCNSL patient after initial intensive chemo-radiotherapy.

Original languageEnglish
Pages (from-to)280-283
Number of pages4
JournalYonsei medical journal
Volume50
Issue number2
DOIs
Publication statusPublished - 2009 Jun 11

Fingerprint

Lymphoma
Stem Cells
Central Nervous System
Drug Therapy
Cytarabine
Etoposide
Ifosfamide
Melphalan
Therapeutics
Radiotherapy
Clinical Trials
Guidelines
Recurrence
Rituximab

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Hong, Sung Jin ; Kim, Jin Seok ; Chang, Jong Hee ; Kim, Kyoung Min ; Kim, Soo Jeong ; Lee, Hye Won ; Cheong, Jone Won ; Lee, Seung Tae ; Min, Yoo Hong. / A successful treatment of relapsed primary CNS lymphoma patient with intraventricular rituximab followed by high-dose chemotherapy with autologous stem cell rescue. In: Yonsei medical journal. 2009 ; Vol. 50, No. 2. pp. 280-283.
@article{5c35f5cda49445ed9b5d1bc34202a391,
title = "A successful treatment of relapsed primary CNS lymphoma patient with intraventricular rituximab followed by high-dose chemotherapy with autologous stem cell rescue",
abstract = "The prognosis for patients with primary central nervous system (CNS) lymphoma (PCNSL) who relapse after the initial response is usually poor. A standard treatment for relapsed PCNSL has not yet been identified because of the heterogeneity of the therapies employed and the lack of large, prospective clinical trials. We describe a 46-year-old relapsed PCNSL patient who was successfully treated with intraventricular applications of rituximab to minimize neurotoxicity, 2 cycles of salvage chemotherapy with etoposide, ifosfamide, and cytarabine (VIA) regimen and high-dose chemotherapy with autologous stem cell rescue. The high-dose chemotherapy consisted of bischloroethylnitrosourea, etoposide, cytarabine, and melphalan (BEAM) regimen. Partial remission was detected after intraventricular rituximab therapy and the patient has been in complete remission without evidence of neurotoxicity for 28 months after high-dose chemotherapy with autologous stem cell rescue. This case indicates a new appropriate treatment guideline in relapsed PCNSL patient after initial intensive chemo-radiotherapy.",
author = "Hong, {Sung Jin} and Kim, {Jin Seok} and Chang, {Jong Hee} and Kim, {Kyoung Min} and Kim, {Soo Jeong} and Lee, {Hye Won} and Cheong, {Jone Won} and Lee, {Seung Tae} and Min, {Yoo Hong}",
year = "2009",
month = "6",
day = "11",
doi = "10.3349/ymj.2009.50.2.280",
language = "English",
volume = "50",
pages = "280--283",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "2",

}

A successful treatment of relapsed primary CNS lymphoma patient with intraventricular rituximab followed by high-dose chemotherapy with autologous stem cell rescue. / Hong, Sung Jin; Kim, Jin Seok; Chang, Jong Hee; Kim, Kyoung Min; Kim, Soo Jeong; Lee, Hye Won; Cheong, Jone Won; Lee, Seung Tae; Min, Yoo Hong.

In: Yonsei medical journal, Vol. 50, No. 2, 11.06.2009, p. 280-283.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A successful treatment of relapsed primary CNS lymphoma patient with intraventricular rituximab followed by high-dose chemotherapy with autologous stem cell rescue

AU - Hong, Sung Jin

AU - Kim, Jin Seok

AU - Chang, Jong Hee

AU - Kim, Kyoung Min

AU - Kim, Soo Jeong

AU - Lee, Hye Won

AU - Cheong, Jone Won

AU - Lee, Seung Tae

AU - Min, Yoo Hong

PY - 2009/6/11

Y1 - 2009/6/11

N2 - The prognosis for patients with primary central nervous system (CNS) lymphoma (PCNSL) who relapse after the initial response is usually poor. A standard treatment for relapsed PCNSL has not yet been identified because of the heterogeneity of the therapies employed and the lack of large, prospective clinical trials. We describe a 46-year-old relapsed PCNSL patient who was successfully treated with intraventricular applications of rituximab to minimize neurotoxicity, 2 cycles of salvage chemotherapy with etoposide, ifosfamide, and cytarabine (VIA) regimen and high-dose chemotherapy with autologous stem cell rescue. The high-dose chemotherapy consisted of bischloroethylnitrosourea, etoposide, cytarabine, and melphalan (BEAM) regimen. Partial remission was detected after intraventricular rituximab therapy and the patient has been in complete remission without evidence of neurotoxicity for 28 months after high-dose chemotherapy with autologous stem cell rescue. This case indicates a new appropriate treatment guideline in relapsed PCNSL patient after initial intensive chemo-radiotherapy.

AB - The prognosis for patients with primary central nervous system (CNS) lymphoma (PCNSL) who relapse after the initial response is usually poor. A standard treatment for relapsed PCNSL has not yet been identified because of the heterogeneity of the therapies employed and the lack of large, prospective clinical trials. We describe a 46-year-old relapsed PCNSL patient who was successfully treated with intraventricular applications of rituximab to minimize neurotoxicity, 2 cycles of salvage chemotherapy with etoposide, ifosfamide, and cytarabine (VIA) regimen and high-dose chemotherapy with autologous stem cell rescue. The high-dose chemotherapy consisted of bischloroethylnitrosourea, etoposide, cytarabine, and melphalan (BEAM) regimen. Partial remission was detected after intraventricular rituximab therapy and the patient has been in complete remission without evidence of neurotoxicity for 28 months after high-dose chemotherapy with autologous stem cell rescue. This case indicates a new appropriate treatment guideline in relapsed PCNSL patient after initial intensive chemo-radiotherapy.

UR - http://www.scopus.com/inward/record.url?scp=66549124921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66549124921&partnerID=8YFLogxK

U2 - 10.3349/ymj.2009.50.2.280

DO - 10.3349/ymj.2009.50.2.280

M3 - Article

C2 - 19430564

AN - SCOPUS:66549124921

VL - 50

SP - 280

EP - 283

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 2

ER -